Wockhardt LtdQ3 FY23
Wockhardt Ltd Q3 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹2,179P/E: 88.8Market Cap: ₹35.4K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Diabetes portfolio (insulin, glargine) in emerging markets expected to drive large growth; current presence ~$50 million with a covered market of $1.5 billion.
- Emerging markets including Latin America, Asia, Russia CIS, and growing MENA region showing improvement and growth.
- UK business growing with increased market share and aggressive product filings (23 filed since 2020, 24 more in next two years).
- Vaccine business with Serum collaboration expected to be a game changer, with reserved 150 million doses capacity and sustained increasing business and profitability.
- Biologicals and biosimilars to grow faster than generics; biologics revenue expected to increase from 20% to 30% of total in next 2-3 years.
- New product launches planned: 14 in India and 25 in UK during 2024-25, including insulin Aspart and other diabetes-related launches.
- US sales maintained via third-party manufacturing, expecting ~40% gross margin with reduced losses.
- Overall growth momentum positive and expected to accelerate in coming years.
See what Wockhardt Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Wockhardt intends to seek external funding primarily for its ongoing clinical trial of WCK 5222, requiring about USD 30 million over the next 12 to 15 months.
- The funding approach includes alternate sources such as debt funding and monetization of non-core assets.
- No specific new equity fundraising is mentioned, but promoter commitment has increased significantly over recent years, with promoter loans converted into equity and additional funds raised via a rights issue in the past.
- For CapEx, apart from clinical trials, there are no manufacturing-related CapEx requirements because manufacturing is outsourced to FDA-approved facilities.
- Overall, they aim to fund R&D and clinical trials through a mix of cash flow, debt, and asset monetization without heavily relying on operating cash flow.
See what Wockhardt Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned CapEx of approximately USD 30 million primarily to complete the clinical trial for WCK 5222 (Page 12, 7).
- No manufacturing CapEx required for WCK 5222 as production is outsourced to FDA-approved European facilities (Page 12).
- Restructuring of US business includes shutting down own manufacturing in Morton Grove, shifting to third-party manufacturing, resulting in savings of about USD 12 million annually (Page 3).
- Ongoing strategic collaboration with Serum for vaccine manufacturing in the UK to drive growth (Page 6).
- Investment focus on R&D, particularly biological and drug discovery, maintaining 8-9% of revenue for R&D with shifting priority from pharmaceutical to biological R&D (Page 9).
- Exploring alternate funding sources including debt funding and asset monetization for clinical trial and R&D investments (Page 7).
Track Wockhardt Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- The US business restructuring is expected to cut losses by approximately USD 10 million, improving bottom-line profitability and aiming for about 40% overall margin in US operations.
- The US business, previously a financial drain, is expected to turn profitable within two years.
- Biologics and biosimilars currently contribute ~20% of revenue, projected to increase to ~30% in 2-3 years, driving faster growth.
- The company targets positive PBT (Profit Before Tax) and cash EBITDA growth by FY24 and significant profitability improvements in FY25.
- New product launches in India, UK, Latin America, MENA, and emerging markets will contribute to revenue growth.
- Total clinical trial investment for WCK 5222 estimated at USD 30 million, funded by alternate sources without impacting cash flow.
- Emphasis on R&D, new drug discovery, and vaccine collaborations (Serum deal) expected to bolster margins and growth.
- Overall, management is positive on accelerating profitable growth and improved financial health over the next 2-3 years.
Order book
The transcript does not explicitly mention the current or expected order book or pending orders for Wockhardt Ltd. However, some relevant points indicating business prospects and volumes include:
- Serum deal guarantees a certain minimum quantity of vaccine doses post-initial phase with expected high margin per dose.
- Company aims to achieve vaccine production of 150 million doses per annum through collaboration with Serum.
- Product launches planned: 14 in India and 25 in the UK during FY24-25.
- Continuous filings and launches in emerging markets with focus on biologicals and biosimilars to grow from 20% to 30% revenue contribution in 2-3 years.
- Clinical trials ongoing for WCK 5222 with global enrollment, intending completion in 15-18 months, supporting future product approvals.
- Manufacturing in US and Canada shifted to third-party companies to improve margins and maintain sales volume.
No direct numeric values on pending order backlog were disclosed.
How does Wockhardt Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureThisWockhardt Ltd
Rev 2Mar 1
How does Wockhardt Ltd rank in Pharmaceuticals & Biotechnology?
Compare Wockhardt Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Wockhardt Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…